Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/63052| metadata.dc.identifier.doi: | https://doi.org/10.56042/ijtk.v22i4.7187 |
| Title: | Majun-e-Suranjan and Habb-e-Azraqi are two Unani compound drugs that are effective and safe in cases of gout - An initial study |
| Authors: | Verma, Radhey Shyam Afridi, Rifat Rehman, Shagufta Ayub, Sadia Qayyum, Zoha Singh, Ravendra Afza, Sheereen Akhtar, Jamal Khan, Asim Ali |
| Keywords: | Gout;Unani compound drugs (Majun-e-Suranjan, Habb-e-Azraqi);efficacy and safety |
| Issue Date: | Dec-2023 |
| Publisher: | NIScPR-CSIR,India |
| IPC Code: | Int Cl23: A61K 36/00, A61K 9/00 |
| Abstract: | Present study evaluated the therapeutic efficacy and safety of two Unani compound drugs Majun-e-Suranjan and Habb-e-Azraqi in cases of gout on modern scientific parameters viz., clinical, biochemical and haematological. This work was conducted at Regional Research Institute of Unani Medicine (RRIUM), Aligarh, during 2014-2019. 71 people were chosen from the pool of patients visiting the outpatient department (OPD). Patients received the Unani medicines Majun-e-Suranjan in a dose of 5.0 g and Habb-e-Azraqi in a dose of 1 pill (250 mg) twice daily after meals for a period of 56-days. One-way analysis of variance (ANOVA) was used for the analysis of data, and the statistical significance of the findings was determined by Dennett's test. The study reveals that the two Unani medicines are safe, non-toxic, and significantly relieve the symptoms of gouty arthritis. It is suggested to conduct more research among a large population. |
| Page(s): | 708-716 |
| ISSN: | 0975-1068 (Online); 0972-5938 (Print) |
| Appears in Collections: | IJTK Vol.22(4) [October 2023] |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJTK 22(4) 708-716.pdf | 817.35 kB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.